A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

NCT05641259 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia

Interventions

DRUG: LP-108
DRUG: Azacitidine

Sponsor

Guangzhou Lupeng Pharmaceutical Company LTD.